Bank of China (Hong Kong) Limited

Company Information

SH
N
600566
JUMPCAN PHARMA

Company Profile

Industry

制造业

Company Introduction

济川药业是集中西医药、中药日化、中药保健三大产业为一体的国家级高新技术企业集团，国家火炬计划医药产业骨干企业，全国制药工业百强企业，上交所A股上市公司，股票代码600566。公司下辖济川药业集团有限公司、上海济嘉投资有限公司。济川药业集团有限公司下辖天济药业、济源医药、蒲地蓝日化、电子商务公司、康煦源保健品、口腔健康研究院等子公司；上海济嘉投资有限公司下辖宁波济嘉投资、东科制药等子公司。济川药业弘扬“同舟共济、海纳百川”的企业精神和“创新、勤奋、共赢”的核心价值观，坚持“四个一”价值创造理念，践行“以人才为根本，以人才为资本，以待遇吸引人才，以事业造就人才，以感情留住人才”的“五以”人才理念，倡导“两项要求”，以特色企业文化引领企业发展。济川药业秉承“用科技捍卫健康”企业使命，倡导“引领前沿、创新精品”研发理念，实施“聚焦五大领域促发展，创新学术营销新理念”，专注于儿科、口腔、呼吸、消化、妇产及其它领域药品的生产和销售。公司拥有10多个剂型、210多个规格品种的国药准字号产品群，有小儿豉翘清热颗粒（同贝）、健胃消食口服液、三拗片等110多个品规列入国家医保目录，68个品规进入国家基药目录。2020年，川芎清脑颗粒、甘海胃康胶囊、左乙拉西坦注射用浓溶液3个品种新进国家医保目录。蒲地蓝、川芎等10多个品种为国内独家品种、独家剂型、江苏省高新技术产品及江苏省名牌产品。“寿牌”商标为中国驰名商标，“同笑”商标为江苏省著名商标。小儿豉翘清热颗粒（同贝）分别荣膺“基层医生最认可的儿科品牌”，入选2020年度临床价值中成药品牌，成为中国药店店员推荐率最高品牌；蒲地蓝消炎口服液获得“最受药店欢迎的明星单品”“家庭用药推荐产品”，荣登2020年“健康中国品牌榜·咽喉口腔用药类”榜首，入选《中药大品种科技竞争力报告（2019）》；新一代质子泵抑制剂雷贝拉唑钠肠溶胶囊（济诺）入选“2020中国医药·品牌榜”；健胃消食口服液荣获“药食同源推荐产品”。以蒲地蓝可炎宁牙膏、蒲地蓝可炎宁抑菌含漱液、蒲地蓝可炎宁抑菌口喷领衔的中药日化产品，不断增强市场核心竞争力，推进大健康事业迅猛发展。济川药业响应健康中国战略，加快推进产业转型升级，以“企业要有一定的发展速度，员工要有一定的收入增长，对政府要有一定的税收贡献，对社会、股东要有一定的责任奉献”为价值创造理念，全面实施中西医药、中药日化、中药保健“三业齐进”和创新科研、资本运作“两翼支撑”的大健康战略布局，推进“两个百年，两个百亿”双百战略高质量发展，努力打造中国一流的综合性药品商业化平台，致力成为中国患者信赖的、领先的综合性制药集团。

Main Business

从事药品的研发、生产和销售。

Legal Representative

曹龙祥

Top Executives

董事长：	曹龙祥
副董事长：	曹飞
董事：	曹伟,黄曲荣
独立董事：	卢超军,姚宏,杨玉海

Top 5 Shareholder

Shareholder name	Nature	Holding	Date
江苏济川控股集团有限公司	流通A股	45.22%	30/09/2024
西藏济川企业管理有限公司	流通A股	10.85%	30/09/2024
曹龙祥	流通A股	5.08%	30/09/2024
香港中央结算有限公司	流通A股	3.84%	30/09/2024
郭伟松	流通A股	1.30%	30/09/2024

Company Secretary

曹伟

Solicitors

国浩律师（上海）事务所

Auditors

立信会计师事务所（特殊普通合伙）

Tel No

0523-89719161

Fax No

0523-89719009

Website

www.jumpcan.com

jcyy@jumpcan.com

Company Address

Register:	湖北省荆州市沙市区园林路时尚豪庭602室
Office:	江苏省泰兴市大庆西路宝塔湾

Listing Date

22/08/2001

Shares Capital

Shares Capital:	921,704,160
Total A Share:	921,704,160
Listed A Share:	915,748,160
Non-tradable A Share:	5,956,000
Other Share:	0
Total B Share:	0
Total H Share:	0

EPS(RMB)*

¥ 3.080

DPS(RMB)*

¥ 1.300

NBV Per Share(RMB)*

¥ 14.482

Market Capitalization(RMB)

27.161B

	Only Chinese content is avaliable
N / N : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only) N : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N / N : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only) N : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
*	Unadjusted Data

Disclaimer:

This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.

Information provided by: etnet
Terms and Conditions